• Subsidiary to Develop Research and Business Opportunities
    Dr. Pierre-Emmanuel Gerard

News & Views

Subsidiary to Develop Research and Business Opportunities

French immune-therapeutics developers Biomunex Pharmaceuticals has established a US subsidiary which will initially focus on facilitating research & development partnerships and business development activities.

“Following our recent licensing agreement with Sanofi for the generation and optimisation of bi- and multi-specific antibody therapeutics, we are excited about ramping up our R&D and partnering activities in the United States with the establishment of Biomunex Inc,” said Dr. Pierre-Emmanuel Gerard, CEO of the Paris-based parent company. “We are delighted to open our US subsidiary in Cambridge, MA, which probably represents the largest biotech cluster in the world, especially in the therapeutic antibody field. Biomunex’ ambition is to develop its product pipeline globally and this first step paves the way for US developments.”

“The establishment of the US subsidiary will contribute to our global R&D objectives by increasing discovery and development partnerships based on the BiXAb® technology with major US academic and industrial teams. Biomunex Inc will also accelerate the preclinical and clinical development of our proprietary BiXAb® antibodies,” added CSO Dr. Eugene Zhukovsky,


Digital Edition

LMUK 49.7 Nov 2024

November 2024

News - Research & Events News   - News & Views Articles - They’re burning the labs... Spotlight Features - Incubators, Freezers & Cooling Equipment - Pumps, Valves & Liquid Hand...

View all digital editions

Events

MEDICA 2024

Nov 11 2024 Dusseldorf, Germany

FILTECH

Nov 12 2024 Cologne, Germany

Intech

Nov 12 2024 Tel Aviv, Israel

analytica China

Nov 18 2024 Shanghai, China

Pharma Asia

Nov 20 2024 Karachi, Pakistan

View all events